spacer
home > ebr > summer 2004 > european life sciences
PUBLICATIONS
European Biopharmaceutical Review

European Life Sciences

As the biotech sector continues to mature, its leading companies will deliver more and more products thereby dramatically improving overall sentiment towards the sector. Despite the investor challenges experienced in recent years, over the past 12-18 months we have witnessed a significant and sustained upswing in the US and European markets, as well as in the biotechnology sector in general. On the whole, the prices of quoted companies in both the US and Europe significantly improved over the year to December 2003, with the NASDAQ Biotech Index up more than 50 per cent over the previous 12 months (1). However, since March 2004 there has been a slight correction in both US and European biotech stocks (as shown in Figure 1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Mark Clement, Chief Executive of Merlin Biosciences

Mark Clement is Chief Executive Officer at Merlin Biosciences. He joined Merlin in March 2000 and serves as Chief Executive. In 1997, he founded MCC Services, a corporate finance consultancy, where he led assignments from nine life sciences companies, including four Fund I investments. In 1992, he co-founded Celsis International plc (a specialist in microbial risk management), where he served as Group Finance Director with responsibility for both finance and European operations. Prior to this, he spent a year at WestLB Panmure as an Associate Director (Corporate Finance). Mark is a Fellow of the Institutes of Chartered Accountants in England and Wales, the Securities Institute and the Insolvency Practitioners Association.

spacer
Mark Clement
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Vaisala Introduces CAB100 Industrial Cabinet for Cleanrooms

Vaisala, a global leader in weather, environmental, and industrial measurements, launches its newest offering for centralized environmental monitoring in cleanrooms: The CAB100 integrates Vaisala’s world-class instruments for monitoring parameters into a simple, pre-configured enclosure.
More info >>

White Papers

The Promise and Challenge of Adaptive Design in Oncology Trials

Medpace

Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research. Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement